Detalles de la búsqueda
1.
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s.
Antimicrob Agents Chemother
; 67(11): e0073723, 2023 11 15.
Artículo
Inglés
| MEDLINE | ID: mdl-37882552
2.
Potential of Long-Acting Products to Transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in Infants, Children, and Adolescents.
Clin Infect Dis
; 75(Suppl 4): S562-S570, 2022 11 21.
Artículo
Inglés
| MEDLINE | ID: mdl-36410381
3.
Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.
Clin Infect Dis
; 75(6): 1037-1045, 2022 09 29.
Artículo
Inglés
| MEDLINE | ID: mdl-35134861
4.
Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.
Antimicrob Agents Chemother
; 65(3)2021 02 17.
Artículo
Inglés
| MEDLINE | ID: mdl-33318014
5.
Antiretroviral Therapy and Adverse Pregnancy Outcomes in People Living with HIV.
N Engl J Med
; 388(4): 344-356, 2023 01 26.
Artículo
Inglés
| MEDLINE | ID: mdl-36720135
6.
Lopinavir and tenofovir interaction observed in non-pregnant adults altered during pregnancy.
J Clin Pharm Ther
; 46(5): 1459-1464, 2021 Oct.
Artículo
Inglés
| MEDLINE | ID: mdl-34254323
7.
Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum.
Antimicrob Agents Chemother
; 64(9)2020 08 20.
Artículo
Inglés
| MEDLINE | ID: mdl-32631820
8.
Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.
Antimicrob Agents Chemother
; 64(4)2020 03 24.
Artículo
Inglés
| MEDLINE | ID: mdl-32015036
9.
Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.
J Antimicrob Chemother
; 75(3): 640-647, 2020 03 01.
Artículo
Inglés
| MEDLINE | ID: mdl-31860112
10.
Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus.
Clin Infect Dis
; 69(7): 1254-1258, 2019 09 13.
Artículo
Inglés
| MEDLINE | ID: mdl-30783649
11.
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.
J Antimicrob Chemother
; 74(5): 1348-1356, 2019 05 01.
Artículo
Inglés
| MEDLINE | ID: mdl-30715324
12.
Praziquantel for the treatment of schistosomiasis during human pregnancy.
Bull World Health Organ
; 96(1): 59-65, 2018 Jan 01.
Artículo
Inglés
| MEDLINE | ID: mdl-29403101
13.
Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
Antimicrob Agents Chemother
; 61(6)2017 06.
Artículo
Inglés
| MEDLINE | ID: mdl-28348149
14.
Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel.
Clin Infect Dis
; 62(6): 761-769, 2016 Mar 15.
Artículo
Inglés
| MEDLINE | ID: mdl-26658057
15.
Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.
Clin Infect Dis
; 61(10): 1582-9, 2015 Nov 15.
Artículo
Inglés
| MEDLINE | ID: mdl-26202768
16.
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
N Engl J Med
; 366(25): 2368-79, 2012 Jun 21.
Artículo
Inglés
| MEDLINE | ID: mdl-22716975
17.
Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.
J Antimicrob Chemother
; 70(1): 217-24, 2015 Jan.
Artículo
Inglés
| MEDLINE | ID: mdl-25261418
18.
Designing drug trials: considerations for pregnant women.
Clin Infect Dis
; 59 Suppl 7: S437-44, 2014 Dec 15.
Artículo
Inglés
| MEDLINE | ID: mdl-25425722
19.
Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age.
Pediatr Infect Dis J
; 43(4): 355-360, 2024 Apr 01.
Artículo
Inglés
| MEDLINE | ID: mdl-38190642
20.
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study.
Lancet HIV
; 11(1): e20-e30, 2024 Jan.
Artículo
Inglés
| MEDLINE | ID: mdl-38061376